Skip to content

SNV4818 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Advanced or metastatic solid tumor with an activating PIK3CA mutation.
* Refractory to or intolerant of available therapies
* Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

* Diagnosis of a primary CNS malignancy
* Active brain metastases or carcinomatous meningitis
* Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
* Inadequate organ function
* Clinically significant ECG abnormalities, including QTcF ≥ 470 ms

Study Location

University Health Network, Princess Margaret Cancer Centre
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contact Study Team

The Ottawa Hospital Cancer Centre
The Ottawa Hospital Cancer Centre
Ottawa, Ontario
Canada

Contact Study Team

Study Sponsored By
Pikavation Therapeutics, Inc.
Participants Required
More Information
Study ID: NCT06736704